BSAM
WST icon

Blue Sky Asset Management’s West Pharmaceutical WST Stock Holding History

Blue Sky Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,300
Closed -$312K – 115
2017
Q2 		$312K Buy
+3,300
New +$304K 0.17% 65

Other funds holding WST

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Blue Sky Asset Management's WST Position: Q3 2017 in Review

Blue Sky Asset Management sold out of West Pharmaceutical (WST) in Q3 2017, closing a stake of 3,300 shares — an estimated $312K sold.

Blue Sky Asset Management first reported a position in WST in Q2 2017 and held it in 1 quarter. The position peaked at $312K in Q2 2017. 302 funds tracked by Wall St. Rank hold WST as of Q3 2017.

  • Blue Sky Asset Management reported no remaining West Pharmaceutical position as of Q3 2017 after selling out during the quarter.
  • Blue Sky Asset Management sold 3,300 West Pharmaceutical shares in Q3 2017, an estimated $312K.
  • Blue Sky Asset Management first reported a position in West Pharmaceutical in Q2 2017 and held it in 1 quarter.
  • Blue Sky Asset Management's West Pharmaceutical position peaked at $312K in Q2 2017.
  • 302 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2017.

Based on Blue Sky Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.